

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization

International Bureau

(43) International Publication Date
09 January 2020 (09.01.2020)



(10) International Publication Number
WO 2020/008206 A1

(51) International Patent Classification:

A61K 31/4164 (2006.01) *A61P 29/00* (2006.01)
A61K 31/4178 (2006.01) *A61P 37/00* (2006.01)
A61P 9/00 (2006.01) *C07D 233/28* (2006.01)
A61P 25/00 (2006.01) *C07D 403/06* (2006.01)

(21) International Application Number:

PCT/GB2019/051903

(22) International Filing Date:

05 July 2019 (05.07.2019)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

1811165.8 06 July 2018 (06.07.2018) GB

(71) Applicant: **METRION BIOSCIENCES LIMITED**

[GB/GB]; Suite 1, Riverside 3, Granta Park, Great Abingdon CB21 6AD (GB).

(72) Inventors: **ROGERS, Marc**; c/o Metrion Biosciences

Limited, Suite 1, Riverside 3, Granta Park, Great Abingdon CB21 6AD (GB). **KIRBY, Robert**; c/o Metrion Biosciences Limited, Suite 1, Riverside 3, Granta Park, Great Abingdon CB21 6AD (GB). **SHOMI, Gakujun**; c/o Metrion Biosciences Limited, Suite 1, Riverside 3, Granta Park, Great Abingdon CB21 6AD (GB). **MATSUO, Takuya**; c/o Metrion Biosciences Limited, Suite 1, Riverside 3, Granta Park, Great Abingdon CB21 6AD (GB). **KOBAYASHI, Satoru**; c/o Metrion Biosciences Limited, Suite 1, Riverside 3, Granta Park, Great Abingdon CB21 6AD (GB). **KANAZAWA, Junichiro**; c/o Metrion Biosciences Limited, Suite 1, Riverside 3, Granta Park, Great Abingdon CB21 6AD (GB). **YAMAOKA, Nobutaka**; c/o Metrion Biosciences Limited, Suite 1, Riverside 3, Granta Park, Great Abingdon CB21 6AD (GB). **TORIZUKA, Makoto**; c/o Metrion Biosciences Limited, Suite 1, Riverside 3, Granta Park, Great Abingdon CB21 6AD (GB). **SUZAWA, Koichi**; c/o Metrion Biosciences Limited, Suite 1, Riverside 3, Granta Park, Great Abingdon CB21 6AD (GB).

(74) Agent: **GIBSON, Mark** et al.; Sagittarius IP, Marlow International, Parkway, Marlow Buckinghamshire SL7 1YL (GB).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))

WO 2020/008206 A1

(54) Title: HETEROCYCLIC SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF

(57) Abstract: The invention relates to heterocyclic sulfonamide derivatives and their use in the treatment and prophylaxis of autoimmune, inflammatory, cardiovascular, neuronal, auditory, renal and metabolic mediated diseases, and to compositions containing said derivatives and processes for their preparation.